Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance.
HIV resistance
bictegravir
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
27
02
2022
accepted:
14
07
2022
pubmed:
17
8
2022
medline:
15
3
2023
entrez:
16
8
2022
Statut:
ppublish
Résumé
Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is approved for treatment of HIV without known resistance to its components. Several studies have demonstrated efficacy of B/F/TAF in patients with nucleoside reverse transcriptase inhibitor (NRTI) resistance-associated mutations (RAMs), mainly identified by proviral DNA testing, but data on the efficacy of B/F/TAF in patients with NRTI RAMs identified in viraemic plasma are limited. We used a retrospective analysis of patients receiving B/F/TAF identified by searching electronic health records with eligibility confirmed by review of individual patient records. Patients included were ≥ 18 years, had 2019 International Antiviral Socitey-USA (IAS-USA) major RAMs affecting NRTIs detected in viraemic plasma prior to starting B/F/TAF and one or more HIV viral load (VL) after starting B/F/TAF. In all, 50 patients met the study criteria: mean age of 54 years, mean proximal CD4 count of 609 cells/μL, 64% male. A total of 46 were virologically suppressed (< 200 copies/mL) when B/F/TAF was initiated, two were treatment-naïve, one stopped prior antiretroviral therapy (ART) and one had a VL of 961 HIV-1 RNA copies/mL on ART. Twenty-nine had one NRTI RAM (24 were M184V/I), nine had two NRTI RAMs, three had three NRTI RAMs, four had four NRTI RAMs, two had five NRTI RAMs, one had six NRTI RAMs, one had seven RAMs and one had eight NRTI RAMs. At the last VL on B/F/TAF, a mean of 18.6 months after starting B/F/TAF, 49 out of 50 had VL < 100 copies/mL and one had a VL of 208 copies/mL at 11 months but only filled 5 months of B/F/TAF. B/F/TAF was effective in maintaining HIV VL suppression in patients with previously documented NRTI RAMs without integrase resistance.
Sections du résumé
BACKGROUND
Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is approved for treatment of HIV without known resistance to its components. Several studies have demonstrated efficacy of B/F/TAF in patients with nucleoside reverse transcriptase inhibitor (NRTI) resistance-associated mutations (RAMs), mainly identified by proviral DNA testing, but data on the efficacy of B/F/TAF in patients with NRTI RAMs identified in viraemic plasma are limited.
METHODS
We used a retrospective analysis of patients receiving B/F/TAF identified by searching electronic health records with eligibility confirmed by review of individual patient records. Patients included were ≥ 18 years, had 2019 International Antiviral Socitey-USA (IAS-USA) major RAMs affecting NRTIs detected in viraemic plasma prior to starting B/F/TAF and one or more HIV viral load (VL) after starting B/F/TAF.
RESULTS
In all, 50 patients met the study criteria: mean age of 54 years, mean proximal CD4 count of 609 cells/μL, 64% male. A total of 46 were virologically suppressed (< 200 copies/mL) when B/F/TAF was initiated, two were treatment-naïve, one stopped prior antiretroviral therapy (ART) and one had a VL of 961 HIV-1 RNA copies/mL on ART. Twenty-nine had one NRTI RAM (24 were M184V/I), nine had two NRTI RAMs, three had three NRTI RAMs, four had four NRTI RAMs, two had five NRTI RAMs, one had six NRTI RAMs, one had seven RAMs and one had eight NRTI RAMs. At the last VL on B/F/TAF, a mean of 18.6 months after starting B/F/TAF, 49 out of 50 had VL < 100 copies/mL and one had a VL of 208 copies/mL at 11 months but only filled 5 months of B/F/TAF.
CONCLUSIONS
B/F/TAF was effective in maintaining HIV VL suppression in patients with previously documented NRTI RAMs without integrase resistance.
Substances chimiques
Anti-Retroviral Agents
0
bictegravir, emtricitabine, tenofovir alafenamide, drug combination
0
Reverse Transcriptase Inhibitors
0
HIV Reverse Transcriptase
EC 2.7.7.49
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
361-365Informations de copyright
© 2022 British HIV Association.
Références
Biktarvy US prescribing information, Gilead Sciences, Foster City, CA. https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf. Accessed January 24, 2022.
Molina JM, Ward D, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018;5:e357-e365.
Daar ES, DeJesus E, Ruane P, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018;5:e347-e356.
Sax PE, Rockstroh JK, Luetkemeyer AF, et al. GS-US-380-4030 investigators. Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus. Clin Infect Dis. 2021;73(2):e485-e493.
Hagins D, Kumar P, Saag M, et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide in black Americans with HIV-1: a randomized phase 3b, multicenter, open-label study. J Acquir Immune Defic Syndr. 2021;88:86-95.
Maggiolo F, Rizzardini G, Molina JM, et al. Bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV aged ≥ 65 years: week 48 results of a phase 3b, open-label trial. Infect Dis Ther. 2021;10:775-788.
Andreatta K, Acosta R, D'Antoni ML, et al. Sustained viral suppression after switch to bictegravir/emtricitabine/tenofovir alafenamide among clinical trial participants with preexisting M184V/I. abstract P123. J Int AIDS Soc. 2020;23(suppl 7):107-108.
Andreatta K, Acosta R, D'Antoni ML, et al. Prevalence and risk factors of preexisting TAMs in clinical trial participants and sustained viral suppression after switching to bictegravir/emtricitabine/tenofovir alafenamide. Abstract PE1/6. EACS 2021, London, UK, October 2021.
Margot N, Ram R, McNicholl I, Haubrich R, Callebaut C. Differential detection of M184V/I between plasma historical HIV genotypes and HIV proviral DNA from PBMCs. J Antimicrob Chemother. 2020;75:2249-2252.
Wensing AM, Calvez V, Ceccherini-Silberstein F, et al. 2019 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2019;27:111-121.
Mican R, de Gea Grela A, Busca C, Bernardino JI, Montes ML, Montejano R, et al. Efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in patients with pre-existing NRTI resistances: real world data. Abstract BPD1/6. EACS 2021, London, UK, October 2021.
Armenia D, Forbici F, Bertoli A, Berno G, Malagnino V, Gagliardini R. Virological response and resistance profile in virologically suppressed HIV-1 infected individuals switching to a bictegravir based treatment in clinical practice. Abstract BPD1/2. EACS 2021, London, UK, October 2021.
Tsai M-S, Sun H-Y, Chen C-P, et al. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide (BIC/F/TAF) for maintenance of viral suppression in adults with historical virological failure and K65N/R mutation. Presented at vIAS July 2021, Abstract 732.
Paton NI, Kityo C, Thompson J, et al. Europe Africa research network for evaluation of second-line therapy (EARNEST) trial team. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial. Lancet HIV. 2017;4:e341-e348.
Sension M, Cahn P, Domingo P, et al. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial. HIV Med. 2013;14:437-444.
Boyd MA, Moore CL, Molina JM, et al. SECOND-LINE study group. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. Lancet HIV. 2015;2:e42-e51.
Aboud M, Kaplan R, Lombaard J, et al. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Lancet Infect Dis. 2019;19:253-264.
Sörstedt E, Carlander C, Flamholc L, et al. Effect of dolutegravir in combination with nucleoside reverse transcriptase inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations. Int J Antimicrob Agents. 2018;51:733-738.
Jary A, Marcelin AG, Charpentier C, et al. M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients. J Antimicrob Chemother. 2020;75:1290-1293.
Paton NI, Musaazi J, Kityo C, et al. Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV. N Engl J Med. 2021;385:330-341.